Tumor suppressor gene

Genprex Provides Business Update and Outlook for 2024

Retrieved on: 
Friday, January 5, 2024

AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today provides a review of its 2023 achievements and a preview of plans for advancing its diabetes and oncology gene therapy programs in 2024.

Key Points: 
  • Our accomplishments in 2023, which also include process improvements in our manufacturing operations and securing new supplies of REQORSA, sets the foundation for a strong 2024."
  • Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Nanoparticle Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles.
  • In May, Genprex completed the Phase 1 portion of the Acclaim-1 clinical trial and reported encouraging results.
  • In October 2023, Genprex entered into a one-year extension to the August 2022 sponsored research agreement with the University of Pittsburgh.

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

Retrieved on: 
Wednesday, January 4, 2023

AUSTIN, Texas, Jan. 4, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

Key Points: 
  • "ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community.
  • The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas.
  • Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Genprex to Present at Upcoming December Investor Conference

Retrieved on: 
Friday, December 2, 2022

AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

Key Points: 
  • Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

Genprex to Present at Upcoming October Investor and Industry Conferences

Retrieved on: 
Friday, October 7, 2022

AUSTIN, Texas, Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022.

Key Points: 
  • AUSTIN, Texas, Oct. 7, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022.
  • For those interested in meeting Genprex management during BIO Europe, please request a meeting through the conference portal or reach out to Kalyn Dabbs at [email protected] .
  • For those interested in meeting Genprex management at LD Micro's Main event, please request a meeting through LD Micro or reach out to Kalyn Dabbs at [email protected] .
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.

Tempus Announces Companion Diagnostic Collaboration with Kartos Therapeutics

Retrieved on: 
Thursday, October 6, 2022

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, a clinical stage biopharmaceutical company, in support of its ongoing Phase II study of navtemadlin (KRT-232) .

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with Kartos Therapeutics, a clinical stage biopharmaceutical company, in support of its ongoing Phase II study of navtemadlin (KRT-232) .
  • Tempus CDx test, which will be developed on Tempus xT platform, will be used to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be eligible for treatment with navtemadlin.
  • We are pleased to be collaborating with the Tempus team to progress our goal of developing innovative therapies that meaningfully improve the lives of patients, said Jesse McGreivy, MD, Chief Executive Officer and Chief Medical Officer at Kartos Therapeutics.
  • We look forward to supporting Kartos diagnostic efforts in identifying cancer patients who could benefit from a more personalized approach to their treatment using a widely-available assay and clinician-friendly tools.

Genprex to Present at Upcoming September Investor Conference

Retrieved on: 
Thursday, September 8, 2022

AUSTIN, Texas, Sept. 8, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Chief Financial Officer, Ryan Confer, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes at the following investor conference in September 2022.

Key Points: 
  • A recording of this presentation will be available for replay on Genprex's website for a period of time.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Retrieved on: 
Friday, August 26, 2022

So far, 6 innovative drugs in Junshi Biosciences pipeline have obtained IND approval from the FDA, and with this newest addition, there are now 7.

Key Points: 
  • So far, 6 innovative drugs in Junshi Biosciences pipeline have obtained IND approval from the FDA, and with this newest addition, there are now 7.
  • Junshi Biosciences currently owns the world-wide exclusive production rights, licensed production rights and sales rights for JS110.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

FORUS Therapeutics Inc ("FORUS") Announces XPOVIO® (selinexor) Is Authorized for Sale by Health Canada

Retrieved on: 
Tuesday, June 7, 2022

This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.

Key Points: 
  • This is the first regulatory approval for XPOVIO in Canada in multiple myeloma and follows recent approvals in Australia, China, South Korea, Singapore and the United States.
  • "The FORUS team is very proud to launch XPOVIO in Canada and bring forth a novel and effective addition to existing regimens for the treatment of relapsed or refractory multiple myeloma.
  • XPOVIO is a registered trademark of Karyopharm Therapeutics Inc. and is used by FORUS Therapeutics Inc. under license.
  • FORUS Therapeutics is a Canadian biopharmaceutical company dedicated to advancing differentiated, novel medicines for hematologic malignancies and other forms of cancer.

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Retrieved on: 
Friday, May 13, 2022

"Antengene has made it a priority to focus on developing therapies for relapsed and refractory patients with cancer.

Key Points: 
  • "Antengene has made it a priority to focus on developing therapies for relapsed and refractory patients with cancer.
  • "We are excited to share this latest and very encouraging data on selinexor at the EHA2022.
  • These data underscore our commitment to elaborating the clinical experience for selinexor and bringing new data to the oncology community."
  • Patients were heavily pre-treated, having received a median of 9.5 prior regimen (range 5-12), with a median time from initial diagnosis of 5.2 years.

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

Retrieved on: 
Thursday, June 24, 2021

Revolution Medicines recently advanced RMC-5552, the companys investigational first-in-class bi-steric mTORC1 inhibitor, into clinical development.

Key Points: 
  • Revolution Medicines recently advanced RMC-5552, the companys investigational first-in-class bi-steric mTORC1 inhibitor, into clinical development.
  • The compound is designed to inhibit mTORC1 and thereby protect the natural tumor suppressor activity of 4EBP1, without the undesirable inhibition of mTORC2.
  • Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.
  • RAS(ON) Inhibitors in development include RMC-6291 and RMC-6236, and a pipeline of research compounds targeting additional RAS variants.